An announcement www.nephjc.com/news/2025/11... #NephJC @kidneyboy.bsky.social and moi hand over the @nephjc.bsky.social reigns to @nephroseeker.medsky.social & @brianrifkin.bsky.social

The need to deprescribe! www.nytimes.com/2025/09/07/h... (gift link) Older peeps and falls, often prescription drugs to blame.

Prof Adeera Levin from @BCRenal education us at @ANZSN 2025 in Perth about models of care in CKD - relationship and knowing your patients is important.

We recorded a podcast with him here www.nephjc.com/freelyfilter... from the last #KidneyWk

Excellent read of the day. Cannot disagree with anything written by Andrew Cohen here: www.ajkd.org/article/S027... in @ajkd.bsky.social Starts off with citations of the dreaded Student Doctor Network and @kidneyboy.bsky.social PB fluids blog.

Recommendations: -Limit nonessential meetings to core hours (eg. 9-4) recognizing that time outside this window is not equitably accessible -Offer asynchronous or hybrid options for professional development & decision-making forums, reducing reliance on physical presence as a proxy for engagement

🤔

30M with aggressive crescentic IgAN. M1E0S1T1C2. 4g proteinuria with Cr 160 umol/L but rising. Induction with IV CYC and pred. Now 1g protein but Cr, now 250 umol/L. Not sure what next :( maybe repeat biopsy? @nephrowhitt.bsky.social @hswapnil.medsky.social @askrenal.bsky.social

We don’t get to discuss every important study that comes out on #NephJC Hence #NephJCShorts www.nephjc.com/news/nephjc-...

My patients live at the margins of society. They don’t have much. Just getting to dialysis three times a week is a big ask. Taking from them to fund tax breaks for the rich is just cruel. I want to be outraged but I just feel like crying.

Holy cow. A $35 copay for every dialysis treatment??? “New Copays: A $35-per-treatment copay for dialysis and CKD patients above the poverty line could cost dialysis patients over $5,000 annually.”

@lachlanmcmichael.bsky.social presenting his first of two talks at @tsanz.bsky.social exploring variation in living donor referral in Australia and New Zealand @anzdataregistry.bsky.social

🔍 New Publication in Kidney International Reports Pleased to share our recently published editorial commentary: “Upstream Causes, Downstream Consequences: Targeting Pre-Dialysis Pathways to Tackle Inequities in Access to Kidney Transplantation” 👉 doi.org/10.1016/j.ek...

@philclayton.bsky.social presenting the new HLA matchability score as part of the proposed new kidney allocation system demonstrating improvement in equity @tsanz.bsky.social @anzdataregistry.bsky.social

This is actually very important given so many of our clinical trials use 'slope of gfr' as a clinical outcome

Amazing

The KDIGO Women and Kidney Health Controversies Conference Report is now available in Kidney International! The report addresses how sex and gender shape kidney health across the lifespan, with a special focus on reproductive health and care equity. Read the report: kdigo.co/Women-and-Ki...

Reducing CKD burden in Europe: first make the elephant apparent! doi.org/10.1093/ckj/...

Anybody know of any good nephrology > #meded > internal medicine conferences in the East Coast of Canada next year around March to May? Hoping to do a Montreal trip but thought I might tie it to a conference.... @hswapnil.medsky.social @askrenal.bsky.social

Post #era25 shenanigans in the #dolomites. Ex #ubc fellows (now nephrology staff around the world) unite! #confidence iykyk

We 'know' this but it's a staggering reminder of how practice changing SGLT2i can be. 26 years of delaying the onset of kidney failure! We have to do better NZ and stop restricting the eligibility for these drugs #era25

Social media as a tool for spreading kidney health from @hdiniz.bsky.social #era25 #inception

Final conference day at #era25

#era26 #era25

Already loving this talk because it's about (the neglected population of) DIALYSIS PATIENTS! #ERA25

I would love to see more of that at ERA26: people posting on Bluesky with recommendations on where to go 🦋🦋🦋

Prof. Anders starting with a banger Diabetic Kidney Disease and Hypertensive Kidney Disease don't exist! 😱 #ERA25

Prof Anders made a case for the (im)balance between workload (hyperfiltration) and nephron mass as the key interaction DM is a risk factor - there are no diabetic HF or diabetic cerebral vascular disease. Most cases are probably multifactorial HTN ckd probably doesnt exist and most are genetic

Very practical session on resistant hypertension by Dr Roland Schneider. Come join us in Hall E2! #era25

Not a topic I would usually go to but I'm trying to be better! Great summary slide re: water use in haemodialysis #era25

It's been a long journey but today we can share the methods and rationale for the #ACHIEVEtrial (Spiro vs placebo for patients with kidney failure receiving maintenance dialysis) and tomorrow we share the results at #era25 journals.sagepub.com/doi/10.1177/...

Although you could say they did not ACHIEVE their goals with this study, massive kudos to the study investigators for seeking to study important outcomes in an often neglected dialysis population. #era25

Vlado Perkovic discussing Sibeprenlimab (APRIL binder) at Late Breaking Clinic Trials II at #era25. Great to see Oceanians (Aus/NZers) on stage!

Fatigue in CKD. Great sessions on incremental HD and PD in Hall C at #era25. (also just a beautiful infographic 😍)

Thank you to #ERA25 for the opportunity to present work on kidney transplant waitlisting

ISGD President @tobias-b-huber.bsky.social advocating for redefining diseases according to endotype rather than histotype on the plenary stage at #ERA25

Very good (often neglected) point about the cost of KRT on patients and family. #era25

The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection

@kevinyau.bsky.social GLP1 agonist master Jedi presenting at #ERA25. 💉GLP1 agonist reduce ED visits and hospitalizations!!! 📉Awesome methods. Best of the session: 💊DDP4 for comparison, IPTW, ICES data. Ticking all the right boxes (EPI nerd). 💊Only 40% on SGLT2i!!! We should flozinate more!!!

#CONFIDENCE trial design #ERA25

The first #ERA25 simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip www.nejm.org/doi/full/10....

So excited to present my poster with the legendary @nephroseeker.medsky.social at #era25 #bartonella #glomerulonephritis #nephsky

10 years of SGLT2i trials shared by Dr Kaitlyn Mayne at #era25!

Also, I'm loving how so many speakers at #era25 have been shouting out other speakers/future sessions ☺️ #collaboration #nephsky

Beautiful summary of the practical implications of the #Flow trial by Dr Peter Rossing at #era25

By the way the #ERA25 hashtag is heating up Go check it out to get the science from Vienna and also find more fresh voices to follow! #NephSky

Ready for day 2 at #era25 💪🏾

Looking forward to an excellent session on genetics. Great intro from the chairs. #era2025

Spicy debate incoming about the need for a cardiologist in the diagnosis and rx of HFpEF in every CKD patient 🔥 #era2025